We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche Plans 2011 MBC Drug Filing After Pertuzumab Meets Endpoint
Roche Plans 2011 MBC Drug Filing After Pertuzumab Meets Endpoint
July 22, 2011
Roche’s first-line metastatic breast cancer (MBC) drug pertuzumab extended the time to disease progression in a key trial and the company plans to seek regulatory approval this year.